Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 10/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 5/20 | 0.40 |
| ▸ | MAOB | P27338 | 5/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 3/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29720433 | 1.00 | MIF (0.40) | MIFCYP26A1MAOBPBRM1CYP19A1 | |
| SCHEMBL19583404 | 0.78 | CYP4F2 (0.32) | — | |
| SCHEMBL346730 | 0.76 | CYP11B2 (0.54) | MIFCYP26A1MAOBCYP19A1MAOA | |
| SCHEMBL22042262 | 0.75 | DRD2 (0.39) | MIFCYP26A1MAOBPBRM1MAOA | |
| SCHEMBL2117296 | 0.74 | ERN1 (0.35) | CYP19A1 | |
| SCHEMBL4265228 | 0.73 | KDM1A (0.42) | MIFMAOBCYP19A1MAOADRD2 | |
| SCHEMBL29648416 | 0.73 | KDM1A (0.42) | MIFMAOBCYP19A1MAOADRD2 | |
| SCHEMBL31344788 | 0.72 | DRD2 (0.37) | MIFCYP26A1MAOBPBRM1MAOA | |
| SCHEMBL27526060 | 0.72 | KDM1A (0.41) | MIFMAOBCYP19A1MAOADRD2 | |
| SCHEMBL5694268 | 0.71 | AKR1B1 (0.39) | MIFCYP26A1MAOBPBRM1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220055986-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-24 | — | — | US | disclosed |
| US-11198672-B2 | Compounds having S1P5 receptor agonistic activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-12-14 | — | — | US | disclosed |
| US-20210087141-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20170327439-A1 | DIHYDRONAPHTHALENE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-16 | — | — | US | disclosed |
| US-20170327439-A1 | DIHYDRONAPHTHALENE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327439-A1 | DIHYDRONAPHTHALENE DERIVATIVE | S1PR5, LPAR5, S1PR1 | MIF 4094/4885CYP26A1 1981/4885MAOB 1638/4885 |
| US-11198672-B2 | Compounds having S1P5 receptor agonistic activity | S1PR5, S1PR1, S1PR4 | MIF 4440/4885CYP26A1 1675/4885MAOB 2121/4885 |
| US-20210087141-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | S1PR5, S1PR1, S1PR4 | MIF 4440/4885CYP26A1 1675/4885MAOB 2121/4885 |
| US-20220055986-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | S1PR5, S1PR1, S1PR4 | MIF 4440/4885CYP26A1 1675/4885MAOB 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.